Advances in cancer research最新文献_第9页

Epigenetic mechanisms and therapeutic advances in breast cancer: From molecular insights to clinical applications. 乳腺癌的表观遗传机制和治疗进展：从分子见解到临床应用。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-09-26 DOI: 10.1016/bs.acr.2025.08.002

Shahid Maqbool Mir, Joseph W Landry, Swadesh K Das, Paul B Fisher

{"title":"Epigenetic mechanisms and therapeutic advances in breast cancer: From molecular insights to clinical applications.","authors":"Shahid Maqbool Mir, Joseph W Landry, Swadesh K Das, Paul B Fisher","doi":"10.1016/bs.acr.2025.08.002","DOIUrl":"10.1016/bs.acr.2025.08.002","url":null,"abstract":"Breast cancer remains the most frequently diagnosed cancer and a leading cause of cancer-related mortality in women globally. While genetic mutations are well-established contributors to breast cancer pathogenesis, accumulating evidence underscores the pivotal role of epigenetic dysregulation including DNA methylation, histone modifications, and non-coding RNAs in driving tumor initiation, progression, metastasis, and therapeutic resistance. These reversible modifications regulate gene expression and chromatin structure without altering the underlying DNA sequence, offering unique opportunities for biomarker discovery and targeted intervention. This review provides a comprehensive overview of the epigenetic landscape in breast cancer, highlighting key molecular players such as BRCA1, RASSF1A, CDH1, and SOX17, and detailing the roles of histone acetylation, methylation, and phosphorylation in chromatin remodeling and gene regulation. The contributions of microRNAs and long non-coding RNAs in modulating cancer phenotypes and therapy responses are also discussed. Furthermore, we explore emerging epigenetic therapies (\"epidrugs\"), their integration with standard chemotherapy and immunotherapy, and the potential of multi-omics approaches in precision oncology. By linking molecular insights to clinical applications, this review emphasizes the promise of epigenetic strategies in advancing personalized treatment for breast cancer patients.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"168 ","pages":"371-438"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145535211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges and opportunities for treatment of medulloblastoma. 髓母细胞瘤治疗的挑战与机遇。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-07-22 DOI: 10.1016/bs.acr.2025.06.006

Meghna Mehta, Dinesh Babu Somasundaram, Anupama Munshi, Rajagopal Ramesh

{"title":"Challenges and opportunities for treatment of medulloblastoma.","authors":"Meghna Mehta, Dinesh Babu Somasundaram, Anupama Munshi, Rajagopal Ramesh","doi":"10.1016/bs.acr.2025.06.006","DOIUrl":"10.1016/bs.acr.2025.06.006","url":null,"abstract":"Medulloblastoma (MB) stands out as the most prevalent, invasive, and biologically heterogeneous pediatric brain tumor. MB accounts for almost 1/4th of all intracranial neoplasms. The prime age of diagnosis is 5-9 years of age; however, the disease is also seen at a later age in approximately 25 % adults. The standard treatment for the disease is comprised of multimodal approaches incorporating surgery, radiation therapy, and adjuvant chemotherapy, which increases the survival to 70-80 %. Despite considerable progress in therapies and novel drug discoveries, 30 % of the survivors succumb to lifelong morbidities and chronic disabilities. A deeper understanding of the disease's molecular landscape has led to the identification of four distinct molecular subgroups: wingless (WNT), sonic hedgehog (SHH), Group 3 and Group 4. This classification, coupled with clinical-pathological assessments of the disease, has enhanced the search for more targeted and effective therapies for MB. In this review, we present an overview of MB, with an emphasis on current treatment options and challenges, utilization of molecular subgroup-specific genetic alterations in development of targeted therapies, including immunotherapy. Additionally, emerging nanomedicine approaches aimed at overcoming the inefficient blood brain barrier (BBB) penetration of drugs used for the treatment of MB, are discussed.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"168 ","pages":"221-268"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145535139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Deciphering the genetic and epigenetic architecture of prostate cancer. 解密前列腺癌的基因和表观遗传结构。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-06-22 DOI: 10.1016/bs.acr.2024.06.001

Sheeraz Un Nazir, Juhi Mishra, Shailendra Kumar Maurya, Negin Ziamiavaghi, Sanika Bodas, Benjamin A Teply, Samikshan Dutta, Kaustubh Datta

{"title":"Deciphering the genetic and epigenetic architecture of prostate cancer.","authors":"Sheeraz Un Nazir, Juhi Mishra, Shailendra Kumar Maurya, Negin Ziamiavaghi, Sanika Bodas, Benjamin A Teply, Samikshan Dutta, Kaustubh Datta","doi":"10.1016/bs.acr.2024.06.001","DOIUrl":"10.1016/bs.acr.2024.06.001","url":null,"abstract":"Prostate cancer, one of the most frequently diagnosed cancers in men, leads to significant mortality worldwide. Its study is important due to the complexity and diversity in its progression, highlighting the urgent need for improved therapeutic strategies. This chapter probes into the genetic and epigenetic factors influencing prostate cancer progression, underscoring the importance of understanding the disease's molecular fundamentals for the development of targeted therapies. It specifically reviews the role of key genetic mutations in genes such as Androgen Receptor, TP53, SPOP, FOXA1 and PTEN which are crucial for the disease onset and a progression. Furthermore, it examines the impact of epigenetic modifications, including DNA methylation and histone modification, which contribute to the cancer's progression by affecting gene expression and cellular behavior. Further, in this chapter we delve into the underlying signaling mechanism, the advancements in targeting genetic and epigenetic alterations in prostate cancer. These findings have revealed promising targets for therapeutic advancements, aiming to understand and identify promising avenues for future therapies. This chapter improves our current understanding of prostate cancer genetic and epigenetic landscape, emphasizing the necessity of advancing our knowledge to refine and expand treatment options for prostate cancer patients.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"161 ","pages":"191-221"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141736277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multiplexed quantitative proteomics in prostate cancer biomarker development. 前列腺癌生物标记物开发中的多重定量蛋白质组学。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-04-25 DOI: 10.1016/bs.acr.2024.04.003

Yuqian Gao, Hyeyoon Kim, Reta Birhanu Kitata, Tai-Tu Lin, Adam C Swensen, Tujin Shi, Tao Liu

{"title":"Multiplexed quantitative proteomics in prostate cancer biomarker development.","authors":"Yuqian Gao, Hyeyoon Kim, Reta Birhanu Kitata, Tai-Tu Lin, Adam C Swensen, Tujin Shi, Tao Liu","doi":"10.1016/bs.acr.2024.04.003","DOIUrl":"10.1016/bs.acr.2024.04.003","url":null,"abstract":"Prostate cancer (PCa) is the most common non-skin cancer among men in the United States. However, the widely used protein biomarker in PCa, prostate-specific antigen (PSA), while useful for initial detection, its use alone cannot detect aggressive PCa and can lead to overtreatment. This chapter provides an overview of PCa protein biomarker development. It reviews the state-of-the-art liquid chromatography-mass spectrometry-based proteomics technologies for PCa biomarker development, such as enhancing the detection sensitivity of low-abundance proteins through antibody-based or antibody-independent protein/peptide enrichment, enriching post-translational modifications such as glycosylation as well as information-rich extracellular vesicles, and increasing accuracy and throughput using advanced data acquisition methodologies. This chapter also summarizes recent PCa biomarker validation studies that applied those techniques in diverse specimen types, including cell lines, tissues, proximal fluids, urine, and blood, developing novel protein biomarkers for various clinical applications, including early detection and diagnosis, prognosis, and therapeutic intervention of PCa.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"161 ","pages":"31-69"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11987045/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141736295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding the molecular regulators of neuroendocrine prostate cancer. 了解神经内分泌性前列腺癌的分子调控因子。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-05-31 DOI: 10.1016/bs.acr.2024.04.006

Sreyashi Bhattacharya, Avery Stillahn, Kaitlin Smith, Michael Muders, Kaustubh Datta, Samikshan Dutta

{"title":"Understanding the molecular regulators of neuroendocrine prostate cancer.","authors":"Sreyashi Bhattacharya, Avery Stillahn, Kaitlin Smith, Michael Muders, Kaustubh Datta, Samikshan Dutta","doi":"10.1016/bs.acr.2024.04.006","DOIUrl":"10.1016/bs.acr.2024.04.006","url":null,"abstract":"Worldwide, prostate cancer (PCa) remains a leading cause of death in men. Histologically, the majority of PCa cases are classified as adenocarcinomas, which are mainly composed of androgen receptor-positive luminal cells. PCa is initially driven by the androgen receptor axis, where androgen-mediated activation of the receptor is one of the primary culprits for disease progression. Therefore, in advanced stage PCa, patients are generally treated with androgen deprivation therapies alone or in combination with androgen receptor pathway inhibitors. However, after an initial decrease, the cancer recurs for majority patients. At this stage, cancer is known as castration-resistant prostate cancer (CRPC). Majority of CRPC tumors still depend on androgen receptor axis for its progression to metastasis. However, in around 20-30% of cases, CRPC progresses via an androgen receptor-independent pathway and is often presented as neuroendocrine cancer (NE). This NE phenotype is highly aggressive with poor overall survival as compared to CRPC adenocarcinoma. NE cancers are resistant to standard taxane chemotherapies, which are often used to treat metastatic disease. Pathologically and morphologically, NE cancers are highly diverse and often co-exist with adenocarcinoma. Due to the lack of proper biomarkers, it is often difficult to make an early diagnosis of this lethal disease. Moreover, increased tumor heterogeneity and admixtures of adeno and NE subtypes in the same tumor make early detection of NE tumors very difficult. With the advancement of our knowledge and sequencing technology, we are now able to better understand the molecular mediators of this transformation pathway. This current study will give an update on how various molecular regulators are involved in these lineage transformation processes and what challenges we are still facing to detect and treat this cancer.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"161 ","pages":"403-429"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141736301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unresolved questions regarding cellular cysteine sources and their possible relationships to ferroptosis. 关于细胞半胱氨酸来源及其与铁蛋白沉积的可能关系的未决问题。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-05-03 DOI: 10.1016/bs.acr.2024.04.001

Elias S J Arnér, Edward E Schmidt

{"title":"Unresolved questions regarding cellular cysteine sources and their possible relationships to ferroptosis.","authors":"Elias S J Arnér, Edward E Schmidt","doi":"10.1016/bs.acr.2024.04.001","DOIUrl":"10.1016/bs.acr.2024.04.001","url":null,"abstract":"Cysteine is required for synthesis of glutathione (GSH), coenzyme A, other sulfur-containing metabolites, and most proteins. In most cells, cysteine comes from extracellular disulfide sources including cystine, glutathione-disulfide, and peptides. The thioredoxin reductase-1 (TrxR1)- or glutathione-disulfide reductase (GSR)-driven enzymatic systems can fuel cystine reduction via thioredoxins, glutaredoxins, or other thioredoxin-fold proteins. Free cystine enters cells thorough the cystine-glutamate antiporter, xCT, but systemically, plasma glutathione-disulfide might predominate as a cystine source. Erastin, inhibiting both xCT and voltage-dependent anion channels, induces ferroptotic cell death, so named because this type of cell death is antagonized by iron-chelators. Many cancer cells seem to be predisposed to ferroptosis, which has been proposed as a targetable cancer liability. Ferroptosis is associated with lipid peroxidation and loss of either glutathione peroxidase-4 (GPX4) or ferroptosis suppressor protein-1 (FSP1), which each prevent accumulation of lipid peroxides. It has been suggested that an xCT inhibition-induced cellular cysteine-deficiency lowers GSH levels, starving GPX4 for reducing power and allowing membrane lipid peroxides to accumulate, thereby causing ferroptosis. Aspects of ferroptosis are however not fully understood and need to be further scrutinized, for example that neither disruption of GSH synthesis, loss of GSH, nor disruption of glutathione disulfide reductase (GSR), triggers ferroptosis in animal models. Here we reevaluate the relationships between Erastin, xCT, GPX4, cellular cysteine and GSH, RSL3 or ML162, and ferroptosis. We conclude that, whereas both Cys and ferroptosis are potential liabilities in cancer, their relationship to each other remains insufficiently understood.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"162 ","pages":"1-44"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141790741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mitochondrial metallopeptidase OMA1 in cancer. 癌症中的线粒体金属肽酶 OMA1

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-05-22 DOI: 10.1016/bs.acr.2024.05.001

Gunjan Purohit, Polash Ghosh, Oleh Khalimonchuk

引用次数: 0

Advancing cancer therapeutics: Integrating scalable 3D cancer models, extracellular vesicles, and omics for enhanced therapy efficacy. 推进癌症治疗：整合可扩展的三维癌症模型、细胞外囊泡和 omics，提高疗效。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-07-20 DOI: 10.1016/bs.acr.2024.07.001

Pedro P Gonçalves, Cláudia L da Silva, Nuno Bernardes

{"title":"Advancing cancer therapeutics: Integrating scalable 3D cancer models, extracellular vesicles, and omics for enhanced therapy efficacy.","authors":"Pedro P Gonçalves, Cláudia L da Silva, Nuno Bernardes","doi":"10.1016/bs.acr.2024.07.001","DOIUrl":"10.1016/bs.acr.2024.07.001","url":null,"abstract":"Cancer remains as one of the highest challenges to human health. However, anticancer drugs exhibit one of the highest attrition rates compared to other therapeutic interventions. In part, this can be attributed to a prevalent use of in vitro models with limited recapitulative potential of the in vivo settings. Three dimensional (3D) models, such as tumor spheroids and organoids, offer many research opportunities to address the urgent need in developing models capable to more accurately mimic cancer biology and drug resistance profiles. However, their wide adoption in high-throughput pre-clinical studies is dependent on scalable manufacturing to support large-scale therapeutic drug screenings and multi-omic approaches for their comprehensive cellular and molecular characterization. Extracellular vesicles (EVs), which have been emerging as promising drug delivery systems (DDS), stand to significantly benefit from such screenings conducted in realistic cancer models. Furthermore, the integration of these nanomedicines with 3D cancer models and omics profiling holds the potential to deepen our understanding of EV-mediated anticancer effects. In this chapter, we provide an overview of the existing 3D models used in cancer research, namely spheroids and organoids, the innovations in their scalable production and discuss how omics can facilitate the implementation of these models at different stages of drug testing. We also explore how EVs can advance drug delivery in cancer therapies and how the synergy between 3D cancer models and omics approaches can benefit in this process.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"163 ","pages":"137-185"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preface. 序言

Advances in cancer research Pub Date : 2024-01-01 DOI: 10.1016/S0065-230X(24)00038-1

O John Semmes, Julius O Nyalwidhe, Swadesh K Das, Paul B Fisher

引用次数: 0

Precision medicine focus on the central nervous system: Non-invasive therapeutic agent delivery with focused ultrasound and microbubbles. 聚焦中枢神经系统的精准医疗：利用聚焦超声波和微气泡进行非侵入性治疗剂输送。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-07-02 DOI: 10.1016/bs.acr.2024.06.003

Padmanabhan Mannangatti, Praveen Bhoopathi, Amit Kumar, Swadesh K Das, Luni Emdad, Paul B Fisher

{"title":"Precision medicine focus on the central nervous system: Non-invasive therapeutic agent delivery with focused ultrasound and microbubbles.","authors":"Padmanabhan Mannangatti, Praveen Bhoopathi, Amit Kumar, Swadesh K Das, Luni Emdad, Paul B Fisher","doi":"10.1016/bs.acr.2024.06.003","DOIUrl":"10.1016/bs.acr.2024.06.003","url":null,"abstract":"Focused ultrasound (FUS) combined with microbubble (MB) treatment is a promising strategy capable of accurately delivering molecular medicines and gene therapy to treat various disease states. The rapid progression and use of FUS technology, from its inception to applications in contemporary medicine, exemplifies the significance and expanding potential of this technology. FUS for drug delivery in the brain can overcome challenging obstacles posed by the blood-brain barrier (BBB) in treating central nervous system (CNS) disorders. Both FUS and magnetic resonance imaging-guided FUS are non-invasive techniques for effectively opening the BBB and enhancing the transportation of molecular medicines and imaging agents into the brain. By integrating MBs into this process, it is possible to disrupt the BBB, facilitating delivery of therapeutic compounds including neuropeptides, proteins, antibodies, chemotherapeutic drugs and recently viruses accurately into the CNS. The safety and versatility of ultrasound makes it an attractive approach for administering molecular medicines, with potential applications extending beyond neurological disorders to include cancer treatment and other medical fields. Preclinical and clinical studies confirm that FUS is safe and efficient in enhancing drug administration, particularly where delivery to a precise location in the CNS is required. Combination therapies that utilize FUS and MBs also provide synergistic responses in cancer therapy. Further refining FUS and MB approaches both from a mechanical and reagent perspective will be forthcoming in the future and prove valuable in precisely defining targets and broadening therapeutic applications. Continued development and applications of FUS and MB technologies will improve therapeutic outcomes and advance patient care in multiple diseases states. This will elevate FUS and MBs from infrequently used medical options to mainstream medical applications.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"164 ","pages":"191-240"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0